Drug development is alive and well in dermatology, and among the interesting data on new drugs/new uses for existing drugs presented in a latebreaker session at AAD this year were:
• Alumis’ ESK-001, a TYK2 inhibitor for psoriasis.
• Johnson & Johnson/Janssen Biotech and Protagonist Therapeutics’ icotrokinra, an oral IL-23R inhibitor for psoriasis.
• Jasper Therapeutics’ briquilimab, an anti-CD117 for chronic spontaneous urticaria.

Dermatology continues to be a hot area for drug development – both new drugs and new uses for existing drugs. Among the studies that stood out this year at AAD were:
• Leo Pharma’s Anzupgo (delgocitinib), a JAK inhibitor in hand eczema
• Regeneron Pharmaceuticals and Sanofi’s Dupixent (dupilumab), an anti-IL-4R in bullous pemphigoid
• Bristol Myers Squibb’s Sotyktu (deucravacitinib), a TYK2 inhibitor for lichen planopilaris
• Lilly’s Olumiant (baricitinib), a JAK inhibitor for adolescent alopecia areata

This conference offered a great update on 13 different drugs, both approved and in development, to treat dry AMD, geography atrophy, wet AMD, and DME.

Here is the medical news to watch for March 24-30, 2025.

2025 Medical Calendar - 2nd Half

Here are some of the things we found interesting in the posters at ASCO-GI

The key focus at this year's Atrial Fibrillation Symposium (AFS) was pulsed field ablation (PFA), though there were also talks on direct-acting anticoagulants, left atrial appendage (LAA) closure, weight loss drugs, and more

Here is a brief overview of the viruses that, right now, appear to be the most concerning: avian H5N1 bird flu, cholera, Covid-19, Marburg, measles (yes, that is still a threat), mpox (formerly monkeypox), and respiratory syncytial virus (RSV)